Abstract
The objectives of this clinical trial are to assess safety, tolerability, and pharmacokinetics of IMU-935. This is a first-in-human, double-blind, randomized, placebo-controlled clinical trial comprising three parts. In part A, healthy volunteers in cohorts of 8 subjects each were enrolled and received single ascending doses of IMU-935 (25 to 400 mg) or placebo (ratio 3:1). In part B, healthy volunteers will receive multiple ascending doses of IMU-935 or placebo for 14 days, and in part C, patients with moderate to severe plaque-type psoriasis will take either two different dose levels of IMU-935 or placebo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
